Olema Oncology to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
Olema Pharmaceuticals (NASDAQ: OLMA) announced that its CEO, Sean P. Bohen, will present at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Pharmaceuticals (NASDAQ: OLMA) announced that its CEO, Sean P. Bohen, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2021, at 10 a.m. ET. The presentation will be available for live streaming, and a replay will be provided thereafter. Olema is focused on developing targeted therapies for women's cancers, with its lead candidate, OP-1250, being evaluated for ER-positive breast cancer in a Phase 1/2 trial.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was +8.03%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bohen, M.D., Ph.D., president and chief executive officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021, at 10 a.m. Eastern Time.
The presentation and Q&A session will be webcast live from the Investors & Media section of Olema’s website. A replay of the webcast will be available.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Contacts
Investor Contact:
ir@olema.com
Media Contact:
Sheryl Seapy, W2O
sseapy@w2ogroup.com
949-903-4750
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.